GSK, Theravance submit sNDA to FDA for fluticasone furoate/vilanterol to treat asthma
The product is marketed under the brand name ‘Breo Ellipta’ and is indicated for asthma patients aged 12 years and older. The sNDA is for approval of two
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.